{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:51:07Z","timestamp":1791334267451,"version":"4.3.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW112-TDU-B-212-144004)"],"award-info":[{"award-number":["MOHW112-TDU-B-212-144004)"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["DMR-111-105"],"award-info":[{"award-number":["DMR-111-105"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["DMR-112-087"],"award-info":[{"award-number":["DMR-112-087"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V111C-188"],"award-info":[{"award-number":["V111C-188"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V112C-164"],"award-info":[{"award-number":["V112C-164"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V113C-166"],"award-info":[{"award-number":["V113C-166"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Council,ROC","award":["MOST 110-2314-B-075-027-MY3"],"award-info":[{"award-number":["MOST 110-2314-B-075-027-MY3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11606-025-09847-2","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:22:04Z","timestamp":1759846924000},"page":"143-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 Inhibitors and Prevention of Cardiovascular Events in Diabetes Patients with and Without Hypertension: A Nationwide Cohort Study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4677-2415","authenticated-orcid":false,"given":"Fu-Shun","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-0679","authenticated-orcid":false,"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6920-8799","authenticated-orcid":false,"given":"Yao-Min","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4563-4341","authenticated-orcid":false,"given":"Chih-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8209-9627","authenticated-orcid":false,"given":"Chii-Min","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"9847_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105836","volume":"172","author":"A Mascolo","year":"2021","unstructured":"Mascolo A, Scavone C, Scisciola L, Chiodini P, Capuano A, Paolisso G. SGLT-2 inhibitors reduce the risk of cerebrovascular\/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies. Pharmacol Res. 2021 Oct;172:105836. https:\/\/doi.org\/10.1016\/j.phrs.2021.105836. Epub 2021 Aug 18. PMID: 34418562.","journal-title":"Pharmacol Res."},{"issue":"7","key":"9847_CR2","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1038\/s41440-024-01649-z","volume":"47","author":"Y Suzuki","year":"2024","unstructured":"Suzuki Y, Kaneko H, Okada A, Komuro J, Fujiu K, Takeda N, Morita H, Ako J, Nishiyama A, Yano Y, Ieda M, Node K, Yasunaga H, Komuro I. Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors. Hypertens Res. 2024 Jul;47(7):1789-1796. https:\/\/doi.org\/10.1038\/s41440-024-01649-z. Epub 2024 Apr 10. PMID: 38600275; PMCID: PMC11224012.","journal-title":"Hypertens Res."},{"issue":"1","key":"9847_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12933-021-01213-w","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Longo M, Scappaticcio L, Caruso P, Esposito K. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovasc Diabetol. 2021 Jan 11;20(1):17. https:\/\/doi.org\/10.1186\/s12933-021-01213-w. PMID: 33430860; PMCID: PMC7798345.","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"9847_CR4","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1016\/S2468-2667(21)00230-9","volume":"7","author":"MO Owolabi","year":"2022","unstructured":"Owolabi MO, Thrift AG, Mahal A, Ishida M, Martins S, Johnson WD, Pandian J, Abd-Allah F, Yaria J, Phan HT, Roth G, Gall SL, Beare R, Phan TG, Mikulik R, Akinyemi RO, Norrving B, Brainin M, Feigin VL; Stroke Experts Collaboration Group. Primary stroke prevention worldwide: translating evidence into action. Lancet Public Health. 2022 Jan;7(1):e74-e85. https:\/\/doi.org\/10.1016\/S2468-2667(21)00230-9. Epub 2021 Oct 29. Erratum in: Lancet Public Health. 2022 Jan;7(1):e14. https:\/\/doi.org\/10.1016\/S2468-2667(21)00281-4. PMID: 34756176; PMCID: PMC8727355.","journal-title":"Lancet Public Health."},{"key":"9847_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/5584_2020_494","volume":"1307","author":"L Bertoccini","year":"2021","unstructured":"Bertoccini L, Baroni MG. GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection. Adv Exp Med Biol. 2021;1307:193-212. https:\/\/doi.org\/10.1007\/5584_2020_494. PMID: 32034729.","journal-title":"Adv Exp Med Biol."},{"issue":"1","key":"9847_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","volume":"94","author":"HJL Heerspink","year":"2018","unstructured":"Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018 Jul;94(1):26-39. https:\/\/doi.org\/10.1016\/j.kint.2017.12.027. Epub 2018 May 5. PMID: 29735306.","journal-title":"Kidney Int."},{"issue":"10166","key":"9847_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-39. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X. Epub 2018 Nov 10.","journal-title":"Lancet."},{"issue":"1","key":"9847_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12933-023-01963-9","volume":"22","author":"D Vistisen","year":"2023","unstructured":"Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, N\u00fa\u00f1ez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nystr\u00f6m T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. https:\/\/doi.org\/10.1186\/s12933-023-01963-9. PMID: 37653496; PMCID: PMC10472675.","journal-title":"Cardiovasc Diabetol."},{"key":"9847_CR9","doi-asserted-by":"publisher","unstructured":"Zhou J, Lee S, Leung KSK, Wai AKC, Liu T, Liu Y, Chang D, Wong WT, Wong ICK, Cheung BMY, Zhang Q, Tse G. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users. ESC Heart Fail. 2022 Apr;9(2):1388\u20131399. https:\/\/doi.org\/10.1002\/ehf2.13830. Epub 2022 Feb 7. PMID: 35132823; PMCID: PMC8934922.","DOI":"10.1002\/ehf2.13830"},{"key":"9847_CR10","doi-asserted-by":"publisher","unstructured":"Richardson TL Jr, Halvorson AE, Hackstadt AJ, Hung AM, Greevy R, Grijalva CG, Elasy TA, Roumie CL. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes. Ann Intern Med. 2023 Jun;176(6):751\u2013760. https:\/\/doi.org\/10.7326\/M22-2751. Epub 2023 May 9. PMID: 37155984; PMCID: PMC10367222.","DOI":"10.7326\/M22-2751"},{"issue":"1","key":"9847_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12967-021-03217-2.PMID:34980154;PMCID:PMC8722333","volume":"20","author":"FS Yen","year":"2022","unstructured":"Yen FS, Wei JC, Chiu LT, Hsu CC, Hwu CM. Diabetes, hypertension, and cardiovascular disease development. J Transl Med. 2022 Jan 3;20(1):9. https:\/\/doi.org\/10.1186\/s12967-021-03217-2. PMID: 34980154; PMCID: PMC8722333.","journal-title":"J Transl Med."},{"issue":"215","key":"9847_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ijcard.2016.04.069","volume":"15","author":"SF Sung","year":"2016","unstructured":"Sung SF, Hsieh CY, Lin HJ, Chen YW, Yang YH, Li CY. Validation of algorithms to identify stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage in an administrative claims database. Int J Cardiol. 2016 Jul 15;215:277-82. https:\/\/doi.org\/10.1016\/j.ijcard.2016.04.069. Epub 2016 Apr 14. PMID: 27128546.","journal-title":"Int J Cardiol."},{"key":"9847_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s11606-007-0310-5","volume":"22","author":"P Meduru","year":"2007","unstructured":"Meduru, P., Helmer, D., Rajan, M., Tseng, C. L., Pogach, L. & Sambamoorthi, U. Chronic illness with complexity: implications for performance measurement of optimal glycemic control. J. Gen. Intern. Med. 22, 408-418 (2007).","journal-title":"J. Gen. Intern. Med."},{"issue":"1","key":"9847_CR14","first-page":"15","volume":"14","author":"BA Young","year":"2008","unstructured":"Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and health care utilization. Am J Manag Care. 2008;14(1):15-23.","journal-title":"Am J Manag Care."},{"issue":"7","key":"9847_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006406.PMID:28733435;PMCID:PMC5586326","volume":"6","author":"YS Lin","year":"2017","unstructured":"Lin YS, Chen TH, Chi CC, Lin MS, Tung TH, Liu CH, Chen YL, Chen MC. Different Implications of Heart Failure, Ischemic Stroke, and Mortality Between Nonvalvular Atrial Fibrillation and Atrial Flutter-a View From a National Cohort Study. J Am Heart Assoc. 2017 Jul 21;6(7):e006406. https:\/\/doi.org\/10.1161\/JAHA.117.006406. PMID: 28733435; PMCID: PMC5586326.","journal-title":"J Am Heart Assoc."},{"issue":"10199","key":"9847_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(19)31893-8","volume":"394","author":"DA Wood","year":"2019","unstructured":"Wood DA. Primary prevention of ischaemic heart disease: populations, individuals, and health professionals. Lancet. 2019 Aug 24;394(10199):685-696. https:\/\/doi.org\/10.1016\/S0140-6736(19)31893-8. PMID: 31448740.","journal-title":"Lancet."},{"key":"9847_CR17","doi-asserted-by":"publisher","unstructured":"Rahman H, Khan SU, Lone AN, Ghosh P, Kunduru M, Sharma S, Sattur S, Kaluski E. Sodium-Glucose Cotransporter-2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta-Analysis of Randomized Trials and Systematic Review. J Am Heart Assoc. 2023 Aug 15;12(16):e030578. https:\/\/doi.org\/10.1161\/JAHA.123.030578. Epub 2023 Aug 10. PMID: 37581396; PMCID: PMC10492958.","DOI":"10.1161\/JAHA.123.030578"},{"key":"9847_CR18","doi-asserted-by":"publisher","unstructured":"Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, Thuresson M, Okami S, Ha KH, Kossack N, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab. 2021 Jan;23(1):75\u201385. https:\/\/doi.org\/10.1111\/dom.14189. Epub 2020 Sep 28. PMID: 32893440; PMCID: PMC7756303.","DOI":"10.1111\/dom.14189"},{"key":"9847_CR19","doi-asserted-by":"publisher","unstructured":"Patorno E, Htoo PT, Glynn RJ, Schneeweiss S, Wexler DJ, Pawar A, Bessette LG, Chin K, Everett BM, Kim SC. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2021 Nov;174(11):1528\u20131541. https:\/\/doi.org\/10.7326\/M21-0893. Epub 2021 Sep 28. Erratum in: Ann Intern Med. 2023 Aug;176(8):1144. https:\/\/doi.org\/10.7326\/L23-0249. PMID: 34570599; PMCID: PMC8969214.","DOI":"10.7326\/M21-0893"},{"key":"9847_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110685","volume":"200","author":"SC Lo","year":"2023","unstructured":"Lo SC, Kornelius E, Liao PL, Huang JY, Yang YS, Huang CN. Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database. Diabetes Res Clin Pract. 2023 Jun;200:110685. https:\/\/doi.org\/10.1016\/j.diabres.2023.110685. Epub 2023 Apr 24. PMID: 37100230.","journal-title":"Diabetes Res Clin Pract."},{"key":"9847_CR21","doi-asserted-by":"publisher","unstructured":"He G, Yang G, Huang X, Luo D, Tang C, Zhang Z. SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: A meta-analysis of randomized controlled trials. Heart Lung. 2023 May-Jun;59:109\u2013116. https:\/\/doi.org\/10.1016\/j.hrtlng.2023.02.009. Epub 2023 Feb 16. PMID: 36801545.","DOI":"10.1016\/j.hrtlng.2023.02.009"},{"key":"9847_CR22","doi-asserted-by":"publisher","unstructured":"Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. J Am Coll Cardiol. 2018 Jun 12;71(23):2628\u20132639. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.009. Epub 2018 Mar 11. PMID: 29540325.","DOI":"10.1016\/j.jacc.2018.03.009"},{"key":"9847_CR23","doi-asserted-by":"publisher","unstructured":"Lee SE, Nam H, Choi HS, Kim H, Kyoung DS, Kim KA. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2022 Jul;46(4):567\u2013577. https:\/\/doi.org\/10.4093\/dmj.2021.0160. Epub 2022 Feb 8. PMID: 35130688; PMCID: PMC9353567.","DOI":"10.4093\/dmj.2021.0160"},{"issue":"2","key":"9847_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/HYPERTENSIONAHA.120.14791","volume":"76","author":"C Yan","year":"2020","unstructured":"Yan C, Thijs L, Cao Y, Trenson S, Zhang ZY, Janssens S, Staessen JA, Feng YM. Opportunities of Antidiabetic Drugs in Cardiovascular Medicine: A Meta-Analysis and Perspectives for Trial Design. Hypertension. 2020 Aug;76(2):420-431. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.14791. Epub 2020 Jul 8. PMID: 32639887.","journal-title":"Hypertension."},{"issue":"9","key":"9847_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2337\/dc22-0938","volume":"45","author":"HC Chang","year":"2022","unstructured":"Chang HC, Kuo TT, Chen YY, Lin YJ, Chang HY, Hung CL, Chung FP. Sodium-Glucose Cotransporter 2 Inhibitors in Cardiovascular and Renal Outcomes in Patients With Diabetes but Without Established Cardiovascular Disease: A Nationwide Population-Based Cohort Study. Diabetes Care. 2022 Sep 1;45(9):129-130. https:\/\/doi.org\/10.2337\/dc22-0938. PMID: 35838320.","journal-title":"Diabetes Care."},{"key":"9847_CR26","doi-asserted-by":"publisher","unstructured":"Li HL, Lip GYH, Feng Q, Fei Y, Tse YK, Wu MZ, Ren QW, Tse HF, Cheung BY, Yiu KH. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021 May 7;20(1):100. https:\/\/doi.org\/10.1186\/s12933-021-01293-8. Erratum in: Cardiovasc Diabetol. 2021 Sep 4;20(1):177. https:\/\/doi.org\/10.1186\/s12933-021-01371-x. PMID: 33962654; PMCID: PMC8106208.","DOI":"10.1186\/s12933-021-01293-8"},{"issue":"7","key":"9847_CR27","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbj\u00f6rnsdottir S. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018 Aug 16;379(7):633-644. https:\/\/doi.org\/10.1056\/NEJMoa1800256. PMID: 30110583.","journal-title":"N Engl J Med."},{"issue":"8","key":"9847_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5005\/japi-11001-0076","volume":"70","author":"R Kovil","year":"2022","unstructured":"Kovil R, Chawla M, Shah T, Sahoo A, Makkar B, Kesavadev J, Seshadri K, Tiwaskar M, Rajput R, Phatak S, Majumdar S, Gupta S. Sodium-glucose Cotransporter-2 Inhibitors in Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus: A Meta-analysis. J Assoc Physicians India. 2022 Aug;70(8):11-12. https:\/\/doi.org\/10.5005\/japi-11001-0076. PMID: 36082726.","journal-title":"J Assoc Physicians India."},{"issue":"4","key":"9847_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2337\/dc21-1113","volume":"45","author":"AK Wright","year":"2022","unstructured":"Wright AK, Carr MJ, Kontopantelis E, Leelarathna L, Thabit H, Emsley R, Buchan I, Mamas MA, van Staa TP, Sattar N, Ashcroft DM, Rutter MK. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Diabetes Care. 2022 Apr 1;45(4):909-918. https:\/\/doi.org\/10.2337\/dc21-1113. PMID: 35100355.","journal-title":"Diabetes Care."},{"key":"9847_CR30","doi-asserted-by":"publisher","unstructured":"Chang HC, Chen YY, Kuo TT, Lin YJ, Chien KL, Chang HY, Hung CL, Chung FP. Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study. J Am Heart Assoc. 2024 Apr 16;13(8):e032397. https:\/\/doi.org\/10.1161\/JAHA.123.032397. Epub 2024 Apr 9. PMID: 38591334; PMCID: PMC11262491.","DOI":"10.1161\/JAHA.123.032397"},{"key":"9847_CR31","doi-asserted-by":"publisher","unstructured":"Stachteas P, Karakasis P, Patoulias D, Clemenza F, Fragakis N, Rizzo M. The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis. Ann Med. 2023;55(2):2304667. https:\/\/doi.org\/10.1080\/07853890.2024.2304667. Epub 2024 Jan 17. PMID: 38233735; PMCID: PMC10798275.","DOI":"10.1080\/07853890.2024.2304667"},{"issue":"9","key":"9847_CR32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S2213-8587(23)00171-7","volume":"11","author":"Y Xie","year":"2023","unstructured":"Xie Y, Bowe B, Xian H, Loux T, McGill JB, Al-Aly Z. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. Lancet Diabetes Endocrinol. 2023 Sep;11(9):644-656. https:\/\/doi.org\/10.1016\/S2213-8587(23)00171-7. Epub 2023 Jul 24. PMID: 37499675.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"9847_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.35995.PMID:36219443;PMCID:PMC9554705","volume":"5","author":"M Zhuo","year":"2022","unstructured":"Zhuo M, D'Andrea E, Paik JM, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Patorno E. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2022 Oct 3;5(10):e2235995. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.35995. PMID: 36219443; PMCID: PMC9554705.","journal-title":"JAMA Netw Open."},{"issue":"7","key":"9847_CR34","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","volume":"31","author":"HD Zhang","year":"2024","unstructured":"Zhang HD, Ding L, Mi LJ, Zhang AK, Zhang K, Jiang ZH, Yu FY, Yan XX, Shen YJ, Tang M. Sodium-glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis. Eur J Prev Cardiol. 2024 May 11;31(7):770-779. https:\/\/doi.org\/10.1093\/eurjpc\/zwad356. PMID: 37966828.","journal-title":"Eur J Prev Cardiol."},{"issue":"2","key":"9847_CR35","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1097\/FJC.0000000000001183","volume":"79","author":"RJ Zheng","year":"2022","unstructured":"Zheng RJ, Wang Y, Tang JN, Duan JY, Yuan MY, Zhang JY. Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol. 2022 Feb 1;79(2):e145-e152. https:\/\/doi.org\/10.1097\/FJC.0000000000001183. PMID: 34813574; PMCID: PMC8895972.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"2","key":"9847_CR36","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/dom.14854","volume":"25","author":"AM Fawzy","year":"2023","unstructured":"Fawzy AM, Rivera-Caravaca JM, Underhill P, Fauchier L, Lip GYH. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database. Diabetes Obes Metab. 2023 Feb;25(2):602-610. https:\/\/doi.org\/10.1111\/dom.14854. Epub 2022 Sep 27. PMID: 36054168; PMCID: PMC10087187.","journal-title":"Diabetes Obes Metab."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09847-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-09847-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09847-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:03:23Z","timestamp":1791331403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-09847-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["9847"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-09847-2","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"These funding agencies had no role in the study design, data collection, and analysis, decision to publish, or manuscript preparation. The writing and preparation of this paper received no funding from any organization, and data analysis was not undertaken by employees of funders or any author who received the funding. The funders did not offer writing support. The corresponding authors had complete access to all data in the study and the final responsibility for the decision to publish.","order":1,"name":"Ethics","label":"Disclaimers","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"This study was approved by the Research Ethics Committee of China Medical University Hospital [CMUH111-REC2-109(CR-1)], and all data were anonymized prior to analysis. As the study used secondary anonymized data, informed consent was waived.","order":2,"name":"Ethics","label":"Human Ethics and Consent to Participate Declarations:","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflict of Interest:","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}